Sheng Zhu1,2, Gang Liu3, Jing Liu1, Qiuying Chen1, Zhiqiang Wang1. 1. Department of Radiology, The First Affiliated Hospital of Jinan University, Guangzhou, China. 2. Department of Radiology, Affiliated Hospital of Xiangnan University, Chenzhou, China. 3. Department of Pediatrics, Affiliated Hospital of Xiangnan University, Chenzhou, China.
Abstract
BACKGROUND: Many studies aimed to evaluate the efficacy and safety of treosulfan-based conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT) compared with other regimens, but different outcomes were reported across studies. AIM: To determine the long-term survival outcomes of treosulfan-based vs. busulfan-based conditioning regimens in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) patients. METHODS: PubMed, Embase, and Cochrane library were searched for studies published prior to December 6, 2019. The fixed-effects model was applied for overall survival (OS), leukemia-free survival (LFS), non-relapse mortality (NRM), acute and chronic graft versus host disease (GvHD). Relapse incidence (RI) was pooled by the use of the random-effects model. RESULTS: Six studies were included (3,982 patients; range, 57-1,956). The pooled HR for OS favored treosulfan (HR=0.80, 95%CI: 0.71-0.90). There was no significant difference in NRM between the two regimens (HR=0.84, 95%CI=0.71-1.01). There was no significant difference in LFS between the two regimens (HR=0.98, 95%CI=0.87-1.12). Treosulfan-based regimens showed a lower risk of aGvHD (HR=0.70, 95%CI=0.59-0.82), but there was no difference for cGvHD (HR=0.94, 95%CI=0.81-1.09). There was no significant difference in RI between the two regimens (HR=0.96, 95%CI=0.71-1.31). There was no publication bias among these studies. CONCLUSION: The current meta-analysis determined that treosulfan-based conditioning regimens could improve the OS in patients with MDS and AML, with lower acute graft-versus-host disease incidence, compared with busulfan-based regimens.
BACKGROUND: Many studies aimed to evaluate the efficacy and safety of treosulfan-based conditioning regimens for allogeneic hematopoietic cell transplantation (allo-HCT) compared with other regimens, but different outcomes were reported across studies. AIM: To determine the long-term survival outcomes of treosulfan-based vs. busulfan-based conditioning regimens in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) patients. METHODS: PubMed, Embase, and Cochrane library were searched for studies published prior to December 6, 2019. The fixed-effects model was applied for overall survival (OS), leukemia-free survival (LFS), non-relapse mortality (NRM), acute and chronic graft versus host disease (GvHD). Relapse incidence (RI) was pooled by the use of the random-effects model. RESULTS: Six studies were included (3,982 patients; range, 57-1,956). The pooled HR for OS favored treosulfan (HR=0.80, 95%CI: 0.71-0.90). There was no significant difference in NRM between the two regimens (HR=0.84, 95%CI=0.71-1.01). There was no significant difference in LFS between the two regimens (HR=0.98, 95%CI=0.87-1.12). Treosulfan-based regimens showed a lower risk of aGvHD (HR=0.70, 95%CI=0.59-0.82), but there was no difference for cGvHD (HR=0.94, 95%CI=0.81-1.09). There was no significant difference in RI between the two regimens (HR=0.96, 95%CI=0.71-1.31). There was no publication bias among these studies. CONCLUSION: The current meta-analysis determined that treosulfan-based conditioning regimens could improve the OS in patients with MDS and AML, with lower acute graft-versus-host disease incidence, compared with busulfan-based regimens.
Authors: Heidrun Boztug; Karl-Walter Sykora; Mary Slatter; Marco Zecca; Paul Veys; Arjan Lankester; Andrew Cant; Roderick Skinner; Jacek Wachowiak; Evgenia Glogova; Ulrike Pötschger; Christina Peters Journal: Pediatr Blood Cancer Date: 2015-09-23 Impact factor: 3.167
Authors: Eneida R Nemecek; Katherine A Guthrie; Mohamed L Sorror; Brent L Wood; Kristine C Doney; Ralf A Hilger; Bart L Scott; Tibor J Kovacsovics; Richard T Maziarz; Ann E Woolfrey; Antonio Bedalov; Jean E Sanders; John M Pagel; Eileen J Sickle; Robert Witherspoon; Mary E Flowers; Frederick R Appelbaum; H Joachim Deeg Journal: Biol Blood Marrow Transplant Date: 2010-05-26 Impact factor: 5.742
Authors: Tapani Ruutu; Liisa Volin; Dietrich W Beelen; Rudolf Trenschel; Juergen Finke; Marc Schnitzler; Jerzy Holowiecki; Sebastian Giebel; Miroslaw Markiewicz; Lutz Uharek; Igor W Blau; Joachim Kienast; Matthias Stelljes; Kajsa Larsson; Axel R Zander; Martin Gramatzki; Roland Repp; Hermann Einsele; Gernot Stuhler; Joachim Baumgart; Heidrun A Mylius; Uwe Pichlmeier; Mathias Freund; Jochen Casper Journal: Haematologica Date: 2011-06-09 Impact factor: 9.941
Authors: Jochen Casper; Daniel Wolff; Wolfgang Knauf; Igor W Blau; Tapani Ruutu; Liisa Volin; Hannes Wandt; Kerstin Schäfer-Eckart; Jerzy Holowiecki; Sebastian Giebel; Johan Aschan; Axel R Zander; Nicolaus Kröger; Inken Hilgendorf; Joachim Baumgart; Heidrun A Mylius; Uwe Pichlmeier; Mathias Freund Journal: J Clin Oncol Date: 2010-05-24 Impact factor: 44.544